LBPH

Longboard Pharmaceuticals, Inc. (LBPH)

Last Price$60.00.0%

Market Cap$2,336.7M

Relative value

$11.2

Overvalued (Relative Value)

81.4%

NTM P/E

(22.0x)

Peer set median: 7.6x

1Y Fwd EV/EBITDA

N/A

Peer set median: 8.1x

Stock quality

6/10

Good

is 81.3% overvalued

undervalued stocks

Start beating the S&P 500

LBPH Relative Value & Intrinsic Value

Key Highlights:

Relative Value vs Current Share Price

As of Dec 13, 2024 LBPH Relative Value is $11.2, which is overvalued by 81.4%, compared to current share price of $60.0.

DCF Value vs Current Share Price

As of Dec 13, 2024 LBPH DCF Value is N/A, which is undervalued by N/A, compared to current share price of $60.0.

Methodology

Price per share, $

Intrinsic value$11.2

Overvalued by81.3%

Current share price

60.0

11.2

not available

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%

S&P Outperformance 19.1%

Next 3M Predicted Return 20.3%

Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

S&P Outperformance -5.5%

Next 3M Predicted Return 10.2%

Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%

S&P Outperformance 15.4%

Next 3M Predicted Return 16.9%

LBPH Valuation Multiples comparison vs Peer Set

LTM

NTM

1Y Forward

2Y Forward

EV/Revenue

General

Valuation Multiple

Financial metrics

Company name

EV/Revenue

Revenue growth

EBITDA margin

Net Income margin

Longboard Pharmaceuticals, Inc.LBPH

Median Peer Set

4.0x

14.8%

(19.3%)

7.5%

Alnylam Pharmaceuticals, Inc.ALNY

BeiGene, Ltd.BGNE

BioMarin Pharmaceutical Inc.BMRN

BioNTech SEBNTX

Regeneron Pharmaceuticals, Inc.REGN

Royalty Pharma plcRPRX

Summit Therapeutics Inc.SMMT

United Therapeutics CorporationUTHR

Vertex Pharmaceuticals IncorporatedVRTX

LBPH Valuation multiples overview

LTM

NTM

1Y Forward

2Y Forward

256,495.0x (as of Dec 13, 2024)

EV/Gross Profit

512,990.1x (as of Dec 13, 2024)

(23.5x) (as of Dec 13, 2024)

(23.5x) (as of Dec 13, 2024)

(31.1x) (as of Dec 13, 2024)

(31.1x) (as of Dec 13, 2024)

292,084.0x (as of Dec 13, 2024)

584,168.1x (as of Dec 13, 2024)

(26.7x) (as of Dec 13, 2024)

(26.7x) (as of Dec 13, 2024)

(35.4x) (as of Dec 13, 2024)

(35.4x) (as of Dec 13, 2024)

(30.6x) (as of Dec 13, 2024)

8.5x (as of Dec 13, 2024)

4.5x (as of Dec 13, 2024)

LBPH Valuation multiples history vs. Peer set

Crunching data... Almost there!

Explore more intrinsic value tools hub for LBPH

DCF value calculator

Peter Lynch Fair Value

Earnings Power Value

Intrinsic Value

Margin of safety

Peter Lynch charts

Earnings growth model

Ben Graham Fair Value

FAQ

What is Longboard Pharmaceuticals, Inc. relative value?

As of Dec 13, 2024, Apple Relative Value is $11.2. This suggests it may be overvalued by 81.4% compared to its current price of around $60.0.

What is Longboard Pharmaceuticals, Inc. DCF (discounted cash flow) valuation?

As of Dec 13, 2024, Longboard Pharmaceuticals, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by N/A to its current price of around $60.0, using a discount rate of 9.4% and terminal growth rate of 3.0%.

What is Longboard Pharmaceuticals, Inc. intrinsic value?

As of Dec 13, 2024, Apple Intrinsic Value is $11.2. This suggests it may be overvalued by 81.3% compared to its current price of around $60.0.